Source comparison
MK-677 vs Prescription HGH: Mechanism, Dosing & Safety Comparison
Mechanism Ghrelin receptor agonist. Stimulates pituitary GH secretion Exogenous recombinant GH. Replaces endogenous hormone MK-677 preserves natural feedback; HGH bypasses it entirely Route of Administration Oral. Once daily Subcutaneous injection. Daily or tw
This comparison does not assign a generated winner or score.
- Mechanism
- Ghrelin receptor agonist. Stimulates pituitary GH secretion
- Exogenous recombinant GH. Replaces endogenous hormone
- MK-677 preserves natural feedback; HGH bypasses it entirely
- Route of Administration
- Oral. Once daily
- Subcutaneous injection. Daily or twice daily
- Oral convenience vs injection precision
- Dosing Range
- 10–25mg daily (research protocols)
- 1–4 IU daily (0.15–1.2mg, depending on indication)
- No direct equivalence. Individual response varies widely
- IGF-1 Elevation
- 40–90% above baseline at 25mg daily
- Dose-dependent. 2 IU ≈ 100–200 ng/mL increase
- Both achieve therapeutic IGF-1 levels; HGH allows tighter control
- Pituitary Suppression
- None. Endogenous GH production preserved
- Significant at supraphysiological doses. May persist post-cessation
- MK-677 does not suppress natural axis; HGH does
- Common Side Effects
- Increased appetite, water retention, mild insulin resistance
- Insulin resistance, joint pain, edema (dose-dependent)
- MK-677 appetite increase universal; HGH risks scale with dose